about
Contrasting Adult and Infant Immune Responses to HIV Infection and VaccinationDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityT-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune SystemBroad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo.Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional PotencyBroadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected womenHIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant.Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.Twist in the Tail: Escape from HIV Neutralising Antibodies at a Single Site Confers Broad Susceptibility to Others.Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site.Progress toward active or passive HIV-1 vaccination.Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.Stabilization of a soluble, native-like trimeric form of an efficiently cleaved Indian HIV-1 clade C envelope glycoproteinEngineering broadly neutralizing antibodies for HIV prevention and therapy.Characterization of two monoclonal antibodies, 38F10 and 44D11, against the major envelope fusion protein of Helicoverpa armigera nucleopolyhedrovirus.Biological roles of glycans.Approaches to the induction of HIV broadly neutralizing antibodies.Genetic and structural analyses of affinity maturation in the humoral response to HIV-1.Evasion of adaptive immunity by HIV through the action of host APOBEC3G/F enzymes.Mammalian cell surface display for monoclonal antibody-based FACS selection of viral envelope proteins.Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding sitePassive immunization with HIV-1-neutralizing antibodies: is it effective and safe?Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity.Conserved HIV Epitopes for an Effective HIV Vaccine.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.Neutralization tiers of HIV-1.Viral subversion of APOBEC3s: Lessons for anti-tumor immunity and tumor immunotherapy.Bone marrow stem cells to destroy circulating HIV: a hypothetical therapeutic strategy.Recent advances in retroviruses via cryo-electron microscopy.
P2860
Q26776518-473BF60F-5CB3-4CB9-809A-010427A88987Q27654848-9E72649E-5A44-4B8B-9C97-DF4F79BCAA30Q33578985-43F49AD9-D137-418B-B9DB-0D161F71AF01Q33592852-622663C6-C336-4413-976D-C6AF99409116Q33594304-072CFDD3-7C4E-4619-974B-4D2582F1189DQ33855697-F754A2F8-FC1D-41A9-ADFD-E611DC15634FQ33867299-095D637D-2510-443F-9427-E6B76CEC0EC3Q34555891-B2911B04-48C7-4C80-B813-71F2230370EDQ35985519-01E0C67A-2705-4D13-B736-84F0CC2477CEQ36246403-FCBEEA14-EBA8-4E99-912B-A0755528E9ACQ36433894-C231BC74-53F1-485B-B593-265BA0BEF916Q36753653-D141FFA0-FA52-4A4E-B942-75A36D9D40FFQ37059216-970AA3FA-8437-4007-94F5-DFDEB2100335Q37102101-FA580BCD-7522-401B-9F7B-187B254CF231Q37363574-E24483ED-5C1E-4C9A-A377-3A21DBE47BBCQ37409244-BB3CDB56-5D5F-4579-AF21-B04A9F761AECQ37549777-5C585005-6BD2-41B4-994A-28484A40276CQ37634061-410567A7-88F0-4844-89AF-2FF33CC3DB63Q37695592-989AA718-19DA-49F0-9875-DB37BE543DB8Q37728775-643BC1A4-C4BA-4879-8722-20D5B916363BQ38712684-ACF4C5D8-9EF1-4E06-A90F-1714F03F7C9DQ38717198-79898AFC-86FB-41FB-BB42-F2170B97FE4EQ38725341-D7825379-69B6-4749-B2E9-024D8565196CQ38936714-2547C78A-818B-48E9-8B2F-6B0AD8CDD5D1Q38936867-8A05DD28-3AF7-43DF-9598-6256FF5C0572Q38992744-E8F5B38C-AAC7-44EE-A6B0-CCE578537BECQ40047192-CC298959-0017-4E24-A271-81DCE320EB73Q40080000-3A6F718A-49A9-477A-BB7E-5291F1E0FB89Q40579418-B125C062-0536-47F0-BCEC-13C44B5388EEQ41919287-8EA103B3-EA05-4A97-AEE9-D11579E6980CQ42084166-FB01E589-58D6-445B-988C-30B9D453F754Q42638889-FA58299A-0799-480B-B793-DFDCC6F2C62BQ47093684-CF141A14-02C8-41F1-ABD4-1C431B0D3DF4Q47110966-33836116-5A0F-400C-94CE-729477A434CFQ47548910-24F41D87-FF7E-426F-B06C-AB5272A72C7BQ47549492-40C8AF2B-6979-4E07-82F4-E78B081FE6B2Q47562235-C7C26B28-9495-462F-8707-91FC3F537344Q47568875-37F6F0C4-D754-43F1-AEFB-59AFC306B57DQ49462231-F7E8EA98-CA1D-4622-A17C-10D288A1469AQ50355158-ADC917C9-0729-448A-AF03-7DDA8313BD0F
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
HIV broadly neutralizing antibody targets
@ast
HIV broadly neutralizing antibody targets
@en
HIV broadly neutralizing antibody targets
@nl
type
label
HIV broadly neutralizing antibody targets
@ast
HIV broadly neutralizing antibody targets
@en
HIV broadly neutralizing antibody targets
@nl
prefLabel
HIV broadly neutralizing antibody targets
@ast
HIV broadly neutralizing antibody targets
@en
HIV broadly neutralizing antibody targets
@nl
P2860
P3181
P1476
HIV broadly neutralizing antibody targets
@en
P2093
Penny L. Moore
P2860
P304
P3181
P356
10.1097/COH.0000000000000153
P407
P577
2015-05-01T00:00:00Z